The Lilly TB Drug Discovery Initiative

The Lilly TB Drug Discovery Initiative's Scientific Steering Committee

- **Dr. Rachel Berhman** – Deputy Director of the Office of Medical Policy within the Center for Drug Evaluation and Research at the Food and Drug Administration (FDA). She also is Director of the Cross-Centers Initiatives Task Force in the Office of the Commissioner. She is an internist with a subspecialty in infectious diseases.

- **Dr. Patrick Brennan** – Distinguished Professor, Mycobacteria Research Laboratories in the Department of Microbiology, Immunology, and Pathology at Colorado State University. In the past 30 years, he has conducted leprosy research and is largely responsible for the progress in the basic research in leprosy today.

- **Dr. Gail Cassell** – Vice President, Lilly Scientific Affairs and Distinguished Research Scholar for Infectious Diseases. Dr. Cassell has been deeply involved in formulating science policy and legislation related to biomedical research and public health. She is a member of the Institute of Medicine (IOM) and serves on the IOM governing board. She recently served a three-year term on the Advisory Board of the Director of the Centers for Disease Control and Prevention and as a member of the Secretary of Health and Human Services Advisory Council of Public Health Preparedness. Dr. Cassell will serve as Chair of the Scientific Steering Committee.

- **Dr. Richard Chaisson** – Professor of Medicine, Epidemiology and International Health at the Johns Hopkins University. He is currently Director of the Johns Hopkins Center for Tuberculosis Research, a multidisciplinary center with more than $60 million in grants for the study of TB from bench to bedside and director of the Consortium to Respond Effectively to the AIDS/TB Epidemic (CREATE), an international research consortium funded by the Bill and Melinda Gates Foundation to assess the impact of novel strategies for controlling HIV-related TB.

- **Dr. Stewart Cole** – Professor of Microbial Pathogenesis at Ecole Polytechnique Federale de Lausanne, School of Life Sciences. He also is Director of the Global Health Institute, a center that will use cutting-edge techniques to seek solutions to treat and prevent TB. Dr. Cole's work on TB, leprosy, AIDS, gas gangrene and bacterial molecular genetics is widely acclaimed throughout the world. He was a leading member of the team of scientists who determined the complete nucleotide sequence for the AIDS virus. He also is considered to be a pioneer in the genomics of TB and leprosy bacilli.

- **Dr. Andrew Dahlem** – Vice President and Chief Operations Officer of Lilly Research Laboratories. He also is a member of the International Society for the Study of Xenobiotics, the Society of Toxicology, and the American Association for the Advancement of Science.

- **Dr. Jacques Grosset** – Professor, Center for Tuberculosis Research at Johns Hopkins University. In the past 45 years he has participated in the development of nearly all new drug regimens used for TB and a number of other mycobacterial diseases, namely leprosy, *M. avium* complex infection in HIV-infected persons, and *M. ulcerans* infection (Buruli ulcer).

- **Dr. Barbara Laughon** – Senior Scientist for TB Drug Development Partnerships in the Office of the Director, Division of Microbiology and Infectious Diseases (DMID) at the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH). She is the primary NIH liaison with The Lilly TB Drug Discovery Initiative. She also serves as Chair of the Scientific Advisory Committee of the TB Alliance and was one of the original founding stakeholders of this public-private partnership. She is an active participant in the STOP-TB Partnership serving in working groups on New Drugs and TB/HIV co-infection.

- **Dr. Zhenkun Ma** – Head of Research at the TB Alliance. He guides the selection of new potential TB drug candidates and oversees preclinical development programs. He is an expert in the discovery aspects of antibacterial medicinal chemistry and in managing development programs of preclinical antibacterial candidates.

- **Dr. Carl Nathan** – Professor and Chair of Department Microbiology and Immunology at Weill Medical College at Cornell University. He is a Fellow at the American Academy of Microbiology and Ellison Medical Foundation Senior Scholar in Global Infectious Diseases.

- **Dr. Alan Palkowitz** – Vice President of Discovery Chemistry Research and Technologies at Lilly. He is responsible for Lilly Global Discovery Chemistry, which is accountable for the discovery of drug candidates targeting oncology, neuroscience, cardiovascular and metabolic diseases.

- **Dr. Christine Sizemore** – Chief of the Tuberculosis and other Mycobacterial Diseases Section at DMID, NIAID, NIH. She is a biologist trained in microbiology, infectious diseases and antimicrobial discovery.

- **Dr. Ken Tanaka** – Vice President of Research and Development at Paratek Pharmaceuticals. He has over 20 years of experience in research and development in the pharmaceutical industry at both large and small pharmaceutical companies.

- **Dr. Paul Wender** – Bergstrom Professor of Chemistry at Stanford University. He is cofounder of the Quantitative Chemical Biology Program, sits on the science advisory boards of the Stanford Molecular Imaging Program and of the Stanford Epithelial Biology Program and an associate of the Program for Molecular and Genetic Medicine. He is a board member of iDDi, a not-for-profit international drug discovery institute focused on unmet medical needs in developing countries.